Enfuvirtide (T-20): potentials and challenges.

Enfuvirtide is a fusion inhibitor used for the treatment of HIV infection. It is an injectable drug, with the patient being responsible for reconstitution as well as injection. The authors present the results of Phase III trials with enfuvirtide.

Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse.

Purpose: There is no published data looking at tolerance of efavirenz (EFV) in patients who abuse cocaine or alcohol (EtOH). The objective of this study was to determine whether individuals with a current or past history of cocaine or EtOH abuse are more likely to experience EFV-induced central nervous system (CNS) side effects that warrant discontinuation of EFV compared with those who do not abuse substances.

Method: Retrospective chart review of all patients who received a nonnucleoside reverse transcriptase inhibitor (NNRTI) at an inner city Ryan White Title III-supported health clinic during 1992-2001.

Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women.

From 1999 to 2001, the overall prevalence of resistance in the antiretroviral (ART)-naive population in St. Louis, Missouri, was 17%. We sought to determine if resistance testing in ART-naive HIV-positive pregnant women identified resistant mutations, which would modify our initial choice of therapy.